AB0048 The Serum Levels of Soluble CD93 is Elevated in Patients with Rheumatoid Arthritis
Background Rheumatoid arthritis (RA) is a systemic autoimmune disease with a heterogeneous clinical spectrum. Because of its molecular complexity, to date, validated biomarkers of severity such as rheumatoid factor or anti-citrullinated peptide antibodies are not capable to identify those patients w...
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2014-06, Vol.73 (Suppl 2), p.819-820 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 820 |
---|---|
container_issue | Suppl 2 |
container_start_page | 819 |
container_title | Annals of the rheumatic diseases |
container_volume | 73 |
creator | Jalili, A. Moghimi, N. Fakhari, S. Khatami, M.M. |
description | Background Rheumatoid arthritis (RA) is a systemic autoimmune disease with a heterogeneous clinical spectrum. Because of its molecular complexity, to date, validated biomarkers of severity such as rheumatoid factor or anti-citrullinated peptide antibodies are not capable to identify those patients who require more intensive treatment1, indicating that finding new biomarker for diagnosis of AR is necessary. CD93 is a glycoprotein which is expressed on the cell surface of many immune cells including hematopoietic stem cells2, monocytes, platelets3. Recent studies have shown that CD93 is shed from the cell surface of monocytes and forms soluble(s)CD93 during inflammation4. sCD93 is enhanced in the serum of patients with systemic sclerosis and correlates with the severity and activity of skin sclerosis. However, the level of this new inflammatory biomarker in patients with RA has not yet been explored. Objectives The objectives of this research were to determine the levels of sCD93 in serum of patients with RA in comparison with normal individuals Methods 34 patients with RA and 35 normal individuals were participated in this study. All the control donors were age- and gender-matched with the patients. Patients were diagnosed at Rheumatology Clinic, Tohid Hospital, Sanandaj, Iran. Serum samples were collected and kept at −80°C until they were analyzed by ELISA. Results The mean age of the patients and control participants were 43±13 and 41±13, respectively. We observed that the serum levels of sCD93 in patients with RA were elevated compared with normal controls. Next, we analyzed the levels of sCD93 in patients with RA and found that the level of sCD93 is much higher in male than female. However, it was similar in both genders in controls individuals. Furthermore, the levels of sCD93 were much higher in smoking patients than non-smoking. Conclusions We demonstrate for the first time that sCD93 is higher in patients with RA than normal individuals and that sCD93 could be used as biomarker for diagnosis of RA. References Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases 2006;65(7):845-51. Jalili A, Marquez-Curtis L, Shirvaikar N, Wysoczynski M, Ratajczak M, Janowska-Wieczorek A. Complement C1q enhances homing-related responses of hematopoietic stem/progenitor cells. Transfusion 2010;50(9):2002-10. Bohlson SS, Si |
doi_str_mv | 10.1136/annrheumdis-2014-eular.5867 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1777977720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4008690941</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1270-d7e39b48cbe017a89957576deb6aa22c3ce54a7a3f08c35b4a72fa3fd43956cd3</originalsourceid><addsrcrecordid>eNqVkM9OwzAMxiMEEmPwDpF27kiaNknFaYy_0iQQGycOUdq6aqauHUk6xI0LL8qTkDIOXDlY9mf5s60fQhNKppQyfq7b1tbQb0rjopjQJIK-0XaaSi4O0IgmXIY2J4doRAhhUZJxcYxOnFsHSSSVI_QyuyQkkV8fn6sa8BJsv8EL2EHjcFfhZdf0eQN4fpUxbBy-bmCnPZTYtPhRewOtd_jN-Bo_DW9o35kSz6yvrfHGnaKjSjcOzn7zGD3fXK_md9Hi4fZ-PltEOY0FiUoBLMsTWeRAqNAyy1KRCl5CzrWO44IVkCZaaFYRWbA0D3VcBVUmLEt5UbIxmuz3bm332oPzat31tg0nFRVCZCFiEqYu9lOF7ZyzUKmtNRtt3xUlaqCp_tBUA031Q1MNNIOb7935Zv0v4zf1eICz</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777977720</pqid></control><display><type>article</type><title>AB0048 The Serum Levels of Soluble CD93 is Elevated in Patients with Rheumatoid Arthritis</title><source>BMJ Journals Online Archive</source><creator>Jalili, A. ; Moghimi, N. ; Fakhari, S. ; Khatami, M.M.</creator><creatorcontrib>Jalili, A. ; Moghimi, N. ; Fakhari, S. ; Khatami, M.M.</creatorcontrib><description>Background Rheumatoid arthritis (RA) is a systemic autoimmune disease with a heterogeneous clinical spectrum. Because of its molecular complexity, to date, validated biomarkers of severity such as rheumatoid factor or anti-citrullinated peptide antibodies are not capable to identify those patients who require more intensive treatment1, indicating that finding new biomarker for diagnosis of AR is necessary. CD93 is a glycoprotein which is expressed on the cell surface of many immune cells including hematopoietic stem cells2, monocytes, platelets3. Recent studies have shown that CD93 is shed from the cell surface of monocytes and forms soluble(s)CD93 during inflammation4. sCD93 is enhanced in the serum of patients with systemic sclerosis and correlates with the severity and activity of skin sclerosis. However, the level of this new inflammatory biomarker in patients with RA has not yet been explored. Objectives The objectives of this research were to determine the levels of sCD93 in serum of patients with RA in comparison with normal individuals Methods 34 patients with RA and 35 normal individuals were participated in this study. All the control donors were age- and gender-matched with the patients. Patients were diagnosed at Rheumatology Clinic, Tohid Hospital, Sanandaj, Iran. Serum samples were collected and kept at −80°C until they were analyzed by ELISA. Results The mean age of the patients and control participants were 43±13 and 41±13, respectively. We observed that the serum levels of sCD93 in patients with RA were elevated compared with normal controls. Next, we analyzed the levels of sCD93 in patients with RA and found that the level of sCD93 is much higher in male than female. However, it was similar in both genders in controls individuals. Furthermore, the levels of sCD93 were much higher in smoking patients than non-smoking. Conclusions We demonstrate for the first time that sCD93 is higher in patients with RA than normal individuals and that sCD93 could be used as biomarker for diagnosis of RA. References Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases 2006;65(7):845-51. Jalili A, Marquez-Curtis L, Shirvaikar N, Wysoczynski M, Ratajczak M, Janowska-Wieczorek A. Complement C1q enhances homing-related responses of hematopoietic stem/progenitor cells. Transfusion 2010;50(9):2002-10. Bohlson SS, Silva R, Fonseca MI, Tenner AJ. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. The Journal of Immunology 2005;175(2):1239-47. Yanaba K, Asano Y, Noda S, Akamata K, Aozasa N, Taniguchi T, et al. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis. British Journal of Dermatology 2012;167(3):542-7. Acknowledgements The authosr thanks to Kurdistan University of Medical Sciences for the financial suports Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5867</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2014-eular.5867</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.819-820</ispartof><rights>2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2014 (c) 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/73/Suppl_2/819.4.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/73/Suppl_2/819.4.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Jalili, A.</creatorcontrib><creatorcontrib>Moghimi, N.</creatorcontrib><creatorcontrib>Fakhari, S.</creatorcontrib><creatorcontrib>Khatami, M.M.</creatorcontrib><title>AB0048 The Serum Levels of Soluble CD93 is Elevated in Patients with Rheumatoid Arthritis</title><title>Annals of the rheumatic diseases</title><description>Background Rheumatoid arthritis (RA) is a systemic autoimmune disease with a heterogeneous clinical spectrum. Because of its molecular complexity, to date, validated biomarkers of severity such as rheumatoid factor or anti-citrullinated peptide antibodies are not capable to identify those patients who require more intensive treatment1, indicating that finding new biomarker for diagnosis of AR is necessary. CD93 is a glycoprotein which is expressed on the cell surface of many immune cells including hematopoietic stem cells2, monocytes, platelets3. Recent studies have shown that CD93 is shed from the cell surface of monocytes and forms soluble(s)CD93 during inflammation4. sCD93 is enhanced in the serum of patients with systemic sclerosis and correlates with the severity and activity of skin sclerosis. However, the level of this new inflammatory biomarker in patients with RA has not yet been explored. Objectives The objectives of this research were to determine the levels of sCD93 in serum of patients with RA in comparison with normal individuals Methods 34 patients with RA and 35 normal individuals were participated in this study. All the control donors were age- and gender-matched with the patients. Patients were diagnosed at Rheumatology Clinic, Tohid Hospital, Sanandaj, Iran. Serum samples were collected and kept at −80°C until they were analyzed by ELISA. Results The mean age of the patients and control participants were 43±13 and 41±13, respectively. We observed that the serum levels of sCD93 in patients with RA were elevated compared with normal controls. Next, we analyzed the levels of sCD93 in patients with RA and found that the level of sCD93 is much higher in male than female. However, it was similar in both genders in controls individuals. Furthermore, the levels of sCD93 were much higher in smoking patients than non-smoking. Conclusions We demonstrate for the first time that sCD93 is higher in patients with RA than normal individuals and that sCD93 could be used as biomarker for diagnosis of RA. References Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases 2006;65(7):845-51. Jalili A, Marquez-Curtis L, Shirvaikar N, Wysoczynski M, Ratajczak M, Janowska-Wieczorek A. Complement C1q enhances homing-related responses of hematopoietic stem/progenitor cells. Transfusion 2010;50(9):2002-10. Bohlson SS, Silva R, Fonseca MI, Tenner AJ. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. The Journal of Immunology 2005;175(2):1239-47. Yanaba K, Asano Y, Noda S, Akamata K, Aozasa N, Taniguchi T, et al. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis. British Journal of Dermatology 2012;167(3):542-7. Acknowledgements The authosr thanks to Kurdistan University of Medical Sciences for the financial suports Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5867</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkM9OwzAMxiMEEmPwDpF27kiaNknFaYy_0iQQGycOUdq6aqauHUk6xI0LL8qTkDIOXDlY9mf5s60fQhNKppQyfq7b1tbQb0rjopjQJIK-0XaaSi4O0IgmXIY2J4doRAhhUZJxcYxOnFsHSSSVI_QyuyQkkV8fn6sa8BJsv8EL2EHjcFfhZdf0eQN4fpUxbBy-bmCnPZTYtPhRewOtd_jN-Bo_DW9o35kSz6yvrfHGnaKjSjcOzn7zGD3fXK_md9Hi4fZ-PltEOY0FiUoBLMsTWeRAqNAyy1KRCl5CzrWO44IVkCZaaFYRWbA0D3VcBVUmLEt5UbIxmuz3bm332oPzat31tg0nFRVCZCFiEqYu9lOF7ZyzUKmtNRtt3xUlaqCp_tBUA031Q1MNNIOb7935Zv0v4zf1eICz</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Jalili, A.</creator><creator>Moghimi, N.</creator><creator>Fakhari, S.</creator><creator>Khatami, M.M.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201406</creationdate><title>AB0048 The Serum Levels of Soluble CD93 is Elevated in Patients with Rheumatoid Arthritis</title><author>Jalili, A. ; Moghimi, N. ; Fakhari, S. ; Khatami, M.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1270-d7e39b48cbe017a89957576deb6aa22c3ce54a7a3f08c35b4a72fa3fd43956cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jalili, A.</creatorcontrib><creatorcontrib>Moghimi, N.</creatorcontrib><creatorcontrib>Fakhari, S.</creatorcontrib><creatorcontrib>Khatami, M.M.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jalili, A.</au><au>Moghimi, N.</au><au>Fakhari, S.</au><au>Khatami, M.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0048 The Serum Levels of Soluble CD93 is Elevated in Patients with Rheumatoid Arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2014-06</date><risdate>2014</risdate><volume>73</volume><issue>Suppl 2</issue><spage>819</spage><epage>820</epage><pages>819-820</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Background Rheumatoid arthritis (RA) is a systemic autoimmune disease with a heterogeneous clinical spectrum. Because of its molecular complexity, to date, validated biomarkers of severity such as rheumatoid factor or anti-citrullinated peptide antibodies are not capable to identify those patients who require more intensive treatment1, indicating that finding new biomarker for diagnosis of AR is necessary. CD93 is a glycoprotein which is expressed on the cell surface of many immune cells including hematopoietic stem cells2, monocytes, platelets3. Recent studies have shown that CD93 is shed from the cell surface of monocytes and forms soluble(s)CD93 during inflammation4. sCD93 is enhanced in the serum of patients with systemic sclerosis and correlates with the severity and activity of skin sclerosis. However, the level of this new inflammatory biomarker in patients with RA has not yet been explored. Objectives The objectives of this research were to determine the levels of sCD93 in serum of patients with RA in comparison with normal individuals Methods 34 patients with RA and 35 normal individuals were participated in this study. All the control donors were age- and gender-matched with the patients. Patients were diagnosed at Rheumatology Clinic, Tohid Hospital, Sanandaj, Iran. Serum samples were collected and kept at −80°C until they were analyzed by ELISA. Results The mean age of the patients and control participants were 43±13 and 41±13, respectively. We observed that the serum levels of sCD93 in patients with RA were elevated compared with normal controls. Next, we analyzed the levels of sCD93 in patients with RA and found that the level of sCD93 is much higher in male than female. However, it was similar in both genders in controls individuals. Furthermore, the levels of sCD93 were much higher in smoking patients than non-smoking. Conclusions We demonstrate for the first time that sCD93 is higher in patients with RA than normal individuals and that sCD93 could be used as biomarker for diagnosis of RA. References Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases 2006;65(7):845-51. Jalili A, Marquez-Curtis L, Shirvaikar N, Wysoczynski M, Ratajczak M, Janowska-Wieczorek A. Complement C1q enhances homing-related responses of hematopoietic stem/progenitor cells. Transfusion 2010;50(9):2002-10. Bohlson SS, Silva R, Fonseca MI, Tenner AJ. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. The Journal of Immunology 2005;175(2):1239-47. Yanaba K, Asano Y, Noda S, Akamata K, Aozasa N, Taniguchi T, et al. Augmented production of soluble CD93 in patients with systemic sclerosis and clinical association with severity of skin sclerosis. British Journal of Dermatology 2012;167(3):542-7. Acknowledgements The authosr thanks to Kurdistan University of Medical Sciences for the financial suports Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.5867</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2014-eular.5867</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0003-4967 |
ispartof | Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.819-820 |
issn | 0003-4967 1468-2060 |
language | eng |
recordid | cdi_proquest_journals_1777977720 |
source | BMJ Journals Online Archive |
title | AB0048 The Serum Levels of Soluble CD93 is Elevated in Patients with Rheumatoid Arthritis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A29%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0048%E2%80%85The%20Serum%20Levels%20of%20Soluble%20CD93%20is%20Elevated%20in%20Patients%20with%20Rheumatoid%20Arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Jalili,%20A.&rft.date=2014-06&rft.volume=73&rft.issue=Suppl%202&rft.spage=819&rft.epage=820&rft.pages=819-820&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2014-eular.5867&rft_dat=%3Cproquest_cross%3E4008690941%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777977720&rft_id=info:pmid/&rfr_iscdi=true |